Please ensure Javascript is enabled for purposes of website accessibility

Why Cullinan Oncology Stock Is Skyrocketing Today

By Keith Speights - Jun 4, 2021 at 11:53AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced encouraging clinical data for its experimental lung cancer drug.

What happened

Shares of Cullinan Oncology (CGEM -3.67%) were skyrocketing 19.5% higher as of 11:21 a.m. EDT on Friday. The big jump came after the company announced additional data for its ongoing phase 1/2a study evaluating CLN-081 in treating non-small cell lung cancer (NSCLC).

So what

Cullinan stated that objective partial response (significant tumor shrinkage) was observed in 21 of the 42 evaluable patients in the phase 1/2a study of CLN-081 across all dose levels. The company said that 76% of all patients showed at least some tumor regression at six weeks.

Scientist looking through a microscope.

Image source: Getty Images.

CLN-081 also appeared to have a relatively good safety profile. Cullinan said that no patients experienced any treatment-related rash of grade 3 (severe) or higher. All adverse events were "manageable with conventional supportive care," according to the company.

Investors were clearly happy with both the efficacy and safety data released by Cullinan. The company's management team was upbeat as well, with CEO Owen Hughes stating, "We remain encouraged with CLN-081's emerging profile."

Now what

Cullinan's data is being featured in an on-demand poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. The biotech stock could have other catalysts on the way. Cullinan hopes to soon file for approvals to initiate clinical studies of experimental drugs CLN-619 and CLN-049. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cullinan Oncology, Inc. Stock Quote
Cullinan Oncology, Inc.
CGEM
$13.64 (-3.67%) $0.52

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
403%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.